CLGN
NASDAQ · Biotechnology
Collplant Biotechnologies Lt
$0.80
+0.05 (+6.65%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.08M | 1.91M | 2.00M |
| Net Income | 160.9K | 134.3K | 123.6K |
| EPS | — | — | — |
| Profit Margin | 7.7% | 7.0% | 6.2% |
| Rev Growth | +11.7% | +10.4% | -4.6% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 3.24M | 2.78M | 2.74M |
| Total Equity | 6.89M | 7.05M | 7.15M |
| D/E Ratio | 0.47 | 0.39 | 0.38 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 232.9K | 222.2K | 203.5K |
| Free Cash Flow | 210.3K | 168.1K | 175.1K |